Krones Ag Adr (KRNTY) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

So, good afternoon and a warm welcome from my side. My name is Olaf Scholz, Head of Investor Relations here at Crohn's. We have presented this morning our preliminary figures of the fiscal year 24. With the strong figures, Crohn's improved all relevant key figures and we also published our targets for 25, which represents a profitable growth strategy of Crohn's. Christoph Klenk and Uta Anders will give you more details about these 24 figures, and in addition to further information, they will show you the published guidance for 25. After the presentation, you will have the opportunity to ask questions. Additionally, I want to inform you that this meeting will not be recorded, and it's also not allowed that you use the recording function in Teams. I think we can start. Yeah, so I hand over to Christoph. Christoph Klink, the floor is yours. Christoph Klink, the floor is yours. Olaf, thank you. Good afternoon. Pleasure to have you all together to the presentation of our numbers. Uta will do as usual together in this audience. And I start immediately jumping in. This is the summary. We don't want to go into that because we tell anything what we have here later on anyway. Those are the numbers which you know. We come to that later on. And I would say that chart is just saying we have achieved all the targets we have set and the governance is achieved. You come to the details. And let's start with order intake and most probably one of the biggest questions everybody has. And I try to give some color on it, where we are with it and how we see the whole thing. I mean, if we look to the last quarter, we had 1.345 billion euro order intake. which was, I would say, to a certain extent, maybe a bit lower than expectation. However, we have been already, let me say, some kind of be...